NCT01422434View on ClinicalTrials.gov

LEO 90105 Ointment in Japanese Subjects With Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

676

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Psoriasis
Interventions
DRUG

LEO 90105 = calcipotriol + betamethasone dipropionate

Applied once daily for 4 weeks.

DRUG

Dovonex® = calcipotriol

Applied twice daily for 4 weeks.

DRUG

Rinderon® - DP = betamethasone dipropionate

Applied once daily for 4 weeks.

Trial Locations (1)

259-1193

Tokai University School of Medicine, Isehara

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

LEO Pharma

INDUSTRY